Passage Bio Reports Q3 Financial Results and Updates

The latest announcement is out from Passage Bio ( (PASG) ).

On November 10, 2025, Passage Bio reported its third-quarter financial results and recent business highlights, including the ongoing enrollment of patients in its upliFT-D clinical trial for PBFT02. The company has aligned with the FDA on an analytical approach for its manufacturing process and is on track to seek regulatory feedback on a registrational trial design in the first half of 2026. Passage Bio’s financial results showed a decrease in net loss and expenses compared to the previous year, with a cash runway projected into the first quarter of 2027.

The most recent analyst rating on (PASG) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Passage Bio stock, see the PASG Stock Forecast page.

Spark’s Take on PASG Stock

According to Spark, TipRanks’ AI Analyst, PASG is a Neutral.

Passage Bio scores moderately low due to its financial challenges, including no revenue and significant cash burn. However, a strong balance sheet and recent corporate event announcements, including program advancements and extended cash runway, provide some optimism. Technical indicators suggest a neutral to bearish sentiment, and traditional valuation metrics are limited due to the company’s stage and lack of profitability.

To see Spark’s full report on PASG stock, click here.

More about Passage Bio

Passage Bio is a clinical stage genetic medicines company focused on developing therapies for neurodegenerative diseases. The company’s primary product candidate, PBFT02, aims to treat conditions such as frontotemporal dementia by elevating progranulin levels to restore lysosomal function and slow disease progression.

Average Trading Volume: 35,860

Technical Sentiment Signal: Sell

Current Market Cap: $19.61M

For an in-depth examination of PASG stock, go to TipRanks’ Overview page.